Agilent SureSelectXT Human Methyl-Seq is the first comprehensive target enrichment system to enable researchers to focus on the regions where methylation is known to impact gene regulation. It targets the most complete Methyl-Seq content, including cancer tissue-specific DMRs, GENCODE promoters, CpG islands, shores and shelves ±4kb, DNaseI hypersensitive sites and RefGenes.
• Delivers more information than methylation microarrays by detecting individual CpGs
• Increases throughput, reduces costs compared to Whole-genome Bisulfite Sequencing
• Reveals methylated regions undetected by RRBS and MeDIP
Receive your quote directly from Agilent Technologies.